Javier Alberto Soto Castillo

Javier Alberto Soto Castillo

Auto-generated profile, based on publicly available information

Javier Alberto Soto Castillo

Universidad de Guayaquil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
ASAbril Samantha Hernández Silva
Abril Samantha Hernández Silva
LBLuis Miguel Palacios Brambila
Luis Miguel Palacios Brambila
SGSamantha Hidalgo García
Samantha Hidalgo García
NPNathy Rodriguez Pequeño
Nathy Rodriguez Pequeño
JCJavier Alberto Soto Castillo
Javier Alberto Soto Castillo
FBFiorella Ibáñez Blanco
Fiorella Ibáñez Blanco
Clinical decision-making in internal medicine has become increasingly complex due to the growing prevalence of multimorbidity, particularly in patients with overlapping cardiovascular and psychiatric conditions. This review analyzes the role of advanced decision-support strategies in enhancing clinical reasoning, diagnostic accuracy, and therapeutic planning in complex cases. A structured methodological approach was applied to evaluate current evidence from high-impact literature, focusing on applications in internal medicine, cardiology, and psychiatry. The findings indicate that decision-support strategies provide their greatest contribution in diagnostic support and risk stratification, where their capacity to process multidimensional clinical data allows for improved identification of patterns and early detection of disease. In cardiology, these approaches demonstrate strong utility in electrocardiographic analysis and cardiovascular risk prediction, while in psychiatry they contribute to treatment response prediction, behavioral assessment, and adherence monitoring. The results also highlight the significant impact of multimorbidity—particularly polypharmacy, cardiovascular burden, and psychiatric comorbidity—on increasing clinical complexity. Despite their potential, the implementation of these strategies is influenced by structural barriers such as limited digital infrastructure, lack of clinician training, interoperability challenges, and economic constraints, especially in healthcare systems such as those of Mexico, Colombia, and Ecuador. The analysis emphasizes that the effectiveness of these tools depends on their integration into a physician-centered model, where clinical judgment remains central.

1 July 2025 in Imperium Académico Multidisciplinary Journal
Verified
Journal Article
Open access
PDF file
MGMartín Gomez-Lujan
Martín Gomez-Lujan
MAMelina Lucia Pineda Aguilar
Melina Lucia Pineda Aguilar
JAJosé Enrique González Araujo
José Enrique González Araujo
DLDaniela María Fernández Lugo
Daniela María Fernández Lugo
IVIvan Alfonso Velasco
Ivan Alfonso Velasco
ALAndrés Marcelo Córdova López
Andrés Marcelo Córdova López
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD) worldwide, and incretin-based therapies have emerged as potential tools for organ protection beyond glucose control. This multicenter prospective study compared renal, metabolic, and cardiovascular outcomes in adults with type 2 diabetes mellitus (T2DM) treated with GLP-1 receptor agonists (GLP-1 RAs) or dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) across Mexico, Colombia, and Ecuador between 2023 and 2024. A total of 512 patients (298 GLP-1 RA, 214 GIP/GLP-1 RA) were followed for 12 months. Dual GIP/GLP-1 therapy showed a significantly smaller annual eGFR decline (−0.6 vs. −1.5 mL/min/1.73 m²; p=0.001) and greater albuminuria reduction (−27.4% vs. −19.0%; p=0.02), with more participants achieving ≥30% UACR reduction (43.9% vs. 34.2%; p=0.04). Improvements in HbA1c (−1.8% vs. −1.2%), body weight (−9.1 vs. −6.4 kg), and systolic blood pressure (−8.4 vs. −6.8 mmHg) were also greater with dual therapy (all p<0.05). Inflammatory and oxidative stress markers decreased more significantly in the GIP/GLP-1 group (IL-6 −34.8%, CRP −42%, MDA −1.4 μmol/L; all p<0.02). Major renal events (CKD stage ≥4 or ≥40% eGFR decline) and cardiovascular outcomes (heart failure hospitalization, myocardial infarction, cardiovascular death) were less frequent with dual agonists, translating to a 28% relative risk reduction in composite cardiorenal events (HR 0.72; 95% CI 0.54–0.96; p=0.02). These findings demonstrate that dual GIP/GLP-1 receptor agonists provide superior renal preservation, metabolic optimization, and cardiorenal protection compared with GLP-1 RAs alone, supporting their integration into early DKD management.

27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
MEMilton Dante Galicia Esparza
Milton Dante Galicia Esparza
GVGerardo Amaya Villagran
Gerardo Amaya Villagran
SGSamantha Hidalgo García
Samantha Hidalgo García
JCJavier Alberto Soto Castillo
Javier Alberto Soto Castillo
RTRichard Adrian Vergara Trujillo
Richard Adrian Vergara Trujillo
MSMaría Betania Contreras Santana
María Betania Contreras Santana
The kidney has traditionally been recognized as an organ responsible for filtration and homeostasis; however, recent evidence highlights its role as a sensitive sensor capable of detecting early systemic alterations. This review analyzes the function of the kidney as a sensor organ through the evaluation of renal biomarkers, with a particular focus on pediatric populations and their interaction with gastrointestinal diseases. A structured narrative review methodology was applied, integrating evidence from nephrology, internal medicine, pediatrics, and gastroenterology. Emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and cystatin C demonstrate greater sensitivity for early detection of renal and systemic alterations compared to traditional markers such as serum creatinine. These biomarkers reflect different pathophysiological mechanisms, including tubular injury, inflammation, and glomerular dysfunction, allowing for a multidimensional assessment of disease processes. The findings also emphasize the relevance of the gut–kidney axis, where gastrointestinal conditions such as dehydration, inflammatory bowel disease, liver dysfunction, and dysbiosis can induce early renal responses. This relationship is particularly significant in pediatric patients, where systemic disturbances may progress rapidly and remain clinically silent in early stages.

27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
DADaniel Ayobami Abe
Daniel Ayobami Abe
HMHeidy Gabriela Rosales Moreira
Heidy Gabriela Rosales Moreira
JCJavier Alberto Soto Castillo
Javier Alberto Soto Castillo
RTRichard Adrian Vergara Trujillo
Richard Adrian Vergara Trujillo
GCGabriela Estefanía Albarracin Calderón
Gabriela Estefanía Albarracin Calderón
DCDavid Vicente Toapanta Chimba
David Vicente Toapanta Chimba
Workplace health systems have emerged as a strategic intersection between occupational medicine, public health, and healthcare management, particularly in response to the growing burden of chronic diseases and the need for sustainable health interventions. This study aimed to analyze the integration of these disciplines within workplace settings and to identify key factors influencing their effectiveness at the population level. A structured narrative review was conducted using a scientific method-based approach, incorporating evidence from international sources with a particular focus on Latin American contexts, including Mexico, Colombia, and Ecuador. The findings indicate that integrated workplace health systems significantly contribute to improved health outcomes, including better chronic disease control, reduced absenteeism, enhanced mental health, and increased organizational productivity. The results also highlight critical barriers such as limited funding, system fragmentation, and lack of trained personnel, as well as facilitating factors including leadership commitment, intersectoral collaboration, and policy support. Comparative analysis revealed variability in implementation across the selected countries, reflecting differences in health system structures and resource allocation.

27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
AAAbril Abigail Arteaga Acosta
Abril Abigail Arteaga Acosta
RTRichard Adrian Vergara Trujillo
Richard Adrian Vergara Trujillo
PVPaola Lizbeth Llango Vásquez
Paola Lizbeth Llango Vásquez
RSRogelio Santos Solís
Rogelio Santos Solís
JCJavier Alberto Soto Castillo
Javier Alberto Soto Castillo
GCGabriela Estefanía Albarracin Calderón
Gabriela Estefanía Albarracin Calderón
The enteric nervous system (ENS), commonly referred to as the “second brain,” has emerged as a key integrative network in clinical medicine. This review analyzes its role beyond gastrointestinal physiology, emphasizing its involvement in neurological, nephrological, and urological conditions through interconnected mechanisms such as the gut–brain, gut–kidney, and gut–bladder axes. A structured analysis of current scientific literature was conducted to identify the main pathways linking ENS dysfunction with multisystem disease, including microbiota dysbiosis, neuroimmune activation, autonomic imbalance, epithelial barrier disruption, and visceral hypersensitivity. The findings demonstrate that while gastrointestinal manifestations remain predominant, ENS-related alterations are strongly associated with systemic inflammation, neurological symptoms, and urinary dysfunction. Additionally, emerging therapeutic strategies highlight the importance of integrative approaches, including dietary interventions, microbiota modulation, neuromodulation, and anti-inflammatory treatments. These results support the concept of the ENS as a central regulator in multisystem physiology and reinforce the need for interdisciplinary clinical reasoning. Understanding the ENS from a systems-based perspective provides valuable insights for improving diagnosis, treatment, and medical education in the context of complex and chronic diseases.